Tokyo - Delayed Quote JPY

Kaken Pharmaceutical Co., Ltd. (4521.T)

Compare
4,292.00
+57.00
+(1.35%)
At close: January 24 at 3:30:00 PM GMT+9

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.
NameTitlePayExercisedYear Born
Mr. Hiroyuki Horiuchi Chairman, President & Representative Director -- -- 1962
Mr. Tomoyuki Koseki Chief Officer of Marketing & Sales Division -- -- --
Satoshi Murakami Chief Officer of Regulatory Affairs Division -- -- --
Mr. Hironobu Ogura Chief of Drug Research Centers -- -- --
Mr. Masashi Suzudo MD & Director -- -- 1962
Hirofumi Fujii Corporate Officer -- -- --
Mitsuru Watanuki Head of Research and Development & Director -- -- 1964
Masaru Ogawa Director of Pharmaceutical Affairs Division -- -- --
Tatsuhiro Harada Deputy Chief Officer of R&D Division & Chief of Drug Research Center -- -- --
Mr. Keizo Kimura Chief Officer of Production Division -- -- --

Kaken Pharmaceutical Co., Ltd.

28-8, Honkomagome 2-chome
Bunkyo-ku
Tokyo, 113-8650
Japan
81 3 5977 5007 https://www.kaken.co.jp
Sector: 
Healthcare
Full Time Employees: 
1,135

Description

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

Corporate Governance

Kaken Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of January 1, 2025 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 7; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 6, 2025 at 4:30 AM UTC

Kaken Pharmaceutical Co., Ltd. Earnings Date

March 28, 2025 at 12:00 AM UTC

Ex-Dividend Date

Recent Events

Related Tickers